Belite Bio (BLTE) Cash & Equivalents (2021 - 2025)

Belite Bio's Cash & Equivalents history runs 5 years deep, the most recent figure standing at $15.6 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 50.62% year-over-year to $15.6 million; the TTM figure through Dec 2025 stood at $15.6 million (down 50.62% YoY), while the FY2025 annual figure was $15.6 million, down 50.62% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $15.6 million, down from $157.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $157.0 million in Q3 2025, with the low at $15.6 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $36.9 million (2022), against an average of $58.7 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents surged 142.67% in 2022, then sank 64.07% in 2024.
• Belite Bio's Cash & Equivalents stood at $17.3 million in 2021, then jumped by 142.67% to $42.1 million in 2022, then soared by 109.45% to $88.2 million in 2023, then tumbled by 64.07% to $31.7 million in 2024, then plunged by 50.62% to $15.6 million in 2025.
• Business Quant data shows BLTE's Cash & Equivalents at $15.6 million in Q4 2025, $157.0 million in Q3 2025, and $31.7 million in Q4 2024.